Gordon Saxty

Co-CEO and CSO at SMIN Therapeutics GmbH

Presenter

Co-CEO/CSO of SMIN Tx. History 9 IND's 2 approved 2/7 of the launched Fragment Drugs Balversa(TM), erdafitinib was fast-tracked/approved in the USA 2018/2019. The first targeted therapy for metastatic bladder cancer (2007-2010). As the first pan-FGFR1-4i without VEGFR2 activity enabled the development of the current selective FGFRi's Capivasertib (TruqapTM) for metastatic breast cancer (combo with faslodex) approval 2023 (2003-2007) Gordon Saxty did his Masters in Medicinal Chemistry at the University of Manchester (UMIST) where, as part of this degree, he also worked at Sanofi-Aventis (formally RPR) (1994-1998) . He then went on to do a PhD in Synthetic Organic Chemistry at Imperial College, London under the supervision of Professor Donald Craig. (1998-2001) Held a position of Associate Director, Medicinal Chemistry at Astex Pharmaceuticals in Cambridge, UK where he worked for just over 12 years on Fragment Based Drug Discovery (FBDD) programmes. (2001-2014) He is also an inventor on 44 published patents and is an author on one of the most accessed Journal of Medicinal Chemistry articles from 2007, on FBDD of PKB/Akt inhibitors. As an individual who has made a significant contribution to industry in the early stages of their career, he was awarded the Royal Society of Chemistry Young Industrialist of the Year Award 2013. He worked as Head of Chemistry in Fidelta, Croatia. For 5 years this work has been in various therapeutic areas, platform technology set up, macrocycles and bRo5 in an integrated drug discovery setting. (2014-2018) He is currently a consultant in MedChem/Drug Discovery and has worked for 14 different companies across 6 countries in the last 5 years (2019-2024).